+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Vertigo Market Report and Forecast 2025-2034

  • PDF Icon

    Report

  • 400 Pages
  • June 2025
  • Region: Global
  • Expert Market Research
  • ID: 6052511
The vertigo market was valued at USD 1.47 Billion in 2024, driven by the rising prevalence of vertigo-related disorders, increasing awareness and advancements in diagnostic technologies across the 8 major markets. It is expected to grow at a CAGR of 4.40% during the forecast period of 2025-2034, and attain a market value of USD 2.26 Billion by 2034.

Vertigo Market Overview

Vertigo is a feeling of dizziness or rotation, resulting from disturbances in the inner ear, brain, or sensory nerve routes. It may vary in intensity and duration, lasting from minutes to days, and is frequently accompanied by nausea, vomiting, headaches, and sweating. Vertigo can be caused by conditions such as BPPV, Meniere’s disease, vestibular neuritis, or migraines, affecting one's daily activities. Signs of this condition consist of lightheadedness, unsteadiness, unusual eye movements, migraines, ringing in the ears, and decreased hearing.

Identifying vertigo requires examining medical history, conducting a physical assessment, and running specific tests to determine the underlying issue. Tests such as the Dix-Hallpike maneuver, audiometric tests, and balance tests are also performed. Electronystagmography or videonystagmography are both options for assessing eye movements and vestibular function.

The treatment of vertigo is determined by the cause and severity of the condition. Maneuvers or medications can be used to treat peripheral vertigo, while diuretics or dietary changes may be needed for Meniere's disease. Vestibular rehab therapy works for persistent vertigo, whereas central vertigo is related to neurological reasons.

Vertigo Market Growth Drivers

Rising Prevalence of Vertigo and Vestibular Disorder Spurs Market Growth

The market is expanding as the occurrence of vertigo and vestibular disorders increases, especially among elderly populations in developed nations. According to the University of California San Francisco, nearly 40% of the United States adults experience vertigo at least once in their lifetime, with women slightly more likely to get it than men. Long-term health issues such as diabetes, heart disease, and neurological disorders are also playing a role in the rise of cases. Healthcare professionals are becoming aware of how vertigo affects quality of life, leading to quicker diagnoses and treatment, and increasing the need for medications, therapies, and rehabilitation services. This is anticipated to result in ongoing market expansion and investment in efficient vertigo treatment options.

Advancements in Technologies and Therapeutic Options to Meet Rising Vertigo Market Demand

Advanced imaging technologies, such as innovations, allow for the precise identification of causes, leading to accurate planning of treatment. In July 2024, Abbott launched the 'Vertigo Coach' app in India, intended to assist vertigo patients. The user-friendly digital health solution provides information on symptoms, triggers, and management strategies, aiming to improve patient-physician interactions. The app includes medication tracking with automated reminders for treatment adherence. Mobile health apps and telemedicine improve healthcare access, particularly in areas with limited services.

Vertigo Market Trends

The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:

Rising Use of Vestibular Rehabilitation Therapy (VRT)

Vestibular rehabilitation therapy (VRT) is a widely used non-pharmacological approach for treating vertigo, which concentrates on enhancing balance and sensory integration to enhance central nervous system performance and counteract vestibular deficiencies. It is gaining popularity as an alternative approach, owing to its minimal side effects.

Increased Research in Herbal and Alternative Therapies

Herbal and alternative remedies such as Ginkgo biloba, ginger root, and turmeric hold the potential to treat vertigo by enhancing blood flow and decreasing inflammation. They have fewer side effects compared to traditional medications, making them appealing to individuals looking for alternative therapies. Research is also being done on the use of acupuncture and homeopathy for the treatment of vertigo.

Growing Interest in Wearable Technology for Monitoring to Boost the Vertigo Market Value

The rise in wearable technology usage is enhancing the monitoring of vertigo symptoms and improving patient care results. Smartwatches and balance monitoring systems keep tabs on body movements, balance, and walking patterns, offering immediate information to patients and healthcare professionals.

Increased Collaboration and Partnerships

Collaborations among pharmaceutical companies, research institutions, and healthcare providers are on the rise in the market. These collaborations allow for the sharing of knowledge, pooling of resources, and exchange of expertise, resulting in the quicker development of innovative treatments and diagnostics.

Vertigo Market Segmentation

The report offers a detailed analysis of the market based on the following segments:

Market Breakup by Type:

  • Peripheral Vertigo
  • Central Vertigo

Market Breakup by Drugs:

  • Anticholinergics
  • Antihistamines
  • Others

Market Breakup by Route of Administration:

  • Oral
  • Parenteral
  • Others

Market Breakup by End User:

  • Hospitals
  • Clinics
  • Others

Market Breakup by Region:

  • United States
  • EU-4 and the United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • India
  • Japan

Vertigo Market Share

Market Segmentation Based on the Drug to Witness Growth

Based on the drugs the market is divided into anticholinergics, antihistamines, and others. Antihistamines such as meclizine and dimenhydrinate are highly favored for treating vertigo, as they effectively reduce dizziness, nausea, and motion sickness by blocking histamine receptors. They are particularly beneficial for patients with vestibular disorders and those experiencing sudden vertigo episodes. Antihistamines are popular due to their rapid onset of action, mild side effects, availability, affordability, and well-established efficacy.

Vertigo Market Analysis by Region

Based on region, the market report covers the United States, EU-4 (Germany, France, Italy, Spain), United Kingdom, Japan, and India.

The United States is expected to dominate the market because of the high prevalence of disorders and a well-developed healthcare system. Awareness of symptoms and a growing elderly population drive the need for treatments. Advancements in digital health technology are also improving the process of diagnosing and managing health conditions.

EU-4 and the United Kingdom are also poised to have a significant market share. Non-drug therapies and technological innovations are favored in the region. In addition, partnerships between pharmaceutical companies and healthcare professionals aid market growth.

The market in Japan and India is rapidly expanding due to support from government efforts. The Japanese market is influenced by the aging population and understanding of illnesses, emphasizing digital health alternatives and non-pharmacological therapies. Improved healthcare access and awareness campaigns in India are driving market growth, with a focus on affordability and alternative treatments.

Leading Players in the Vertigo Market

The key features of the market report include patent analysis, clinical trials analysis, grants analysis, funding, and investment analysis, as well as strategic initiatives by the leading players. The major companies in the market are as follows:

Sanofi S.A

Sanofi S.A., a French multinational healthcare company established in 1973 and based in Paris, focuses on the discovery, development, manufacturing, and marketing of medicines, vaccines, and consumer healthcare products for a range of conditions such as cancer, rare diseases, multiple sclerosis, and bacterial and viral diseases protection.

Pfizer Inc

Pfizer, an American pharmaceutical corporation founded in 1849 and headquartered in Manhattan, New York City, specializes in discovering, developing, manufacturing, and commercializing biopharmaceuticals for various conditions, including cardiovascular, metabolic, pain, women's health, cancer, inflammation, immune disorders, and rare diseases. They also offer sterile injectable pharmaceuticals, biosimilars, APIs, and contract manufacturing services.

Sound Pharmaceuticals

Seattle-based biopharmaceutical company Sound Pharmaceuticals (SPI) completed its Phase 3 clinical trial for SPI-1005, a novel anti-inflammatory drug designed to treat Meniere's Disease in July 2024. Meniere's Disease is characterized by vertigo, hearing loss, and tinnitus caused by swelling in the inner ear. SPI-1005, taken orally twice daily, is the only potential treatment shown to improve hearing loss and tinnitus in Meniere's Disease patients, as demonstrated in Phase 1b and 2b studies.

Other players in the market are Viatris Inc., Casper Pharma LLC, Apsen Farmaceutica S.A., and Auris Medical AG.

Key Questions Answered in the Vertigo Market Report

  • What was the vertigo market value in 2024?
  • What is the vertigo market forecast outlook for 2025-2034?
  • What are the regional markets covered in the report?
  • What is the market segmentation based on the drugs?
  • What is the market segmentation based on the end users?
  • What is the market breakup based on the type?
  • What is the market breakup based on the route of administration?
  • What are the major factors aiding the vertigo market demand?
  • How has the market performed so far and how is it anticipated to perform in the coming years?
  • What are the major drivers, opportunities, and restraints in the market?
  • What are the major trends influencing the market?
  • Which regional market is expected to dominate the market share in the forecast period?
  • Which country is likely to experience elevated growth during the forecast period?
  • Who are the key players involved in the vertigo market?
  • What are the current unmet needs and challenges in the market?
  • How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?

This product will be delivered within 3-5 business days.

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Vertigo Market Overview - 8 Major Markets
3.1 Vertigo Market Historical Value (2018-2024)
3.2 Vertigo Market Forecast Value (2025-2034)
4 Vendor Positioning Analysis
4.1 Key Vendors
4.2 Prospective Leaders
4.3 Niche Leaders
4.4 Disruptors
5 Vertigo Overview
5.1 Guidelines and Stages
5.2 Pathophysiology
5.3 Screening and Diagnosis
5.4 Treatment Pathway
6 Patient Profile
6.1 Patient Profile Overview
6.2 Patient Psychology and Emotional Impact Factors
6.3 Risk Assessment and Treatment Success Rate
7 Vertigo Market - Epidemiology Scenario and Forecast - 8 Major Markets
7.1 8MM Epidemiology Scenario Overview (2018-2034)
7.1.1 Prevalence, by Country
7.1.1.1 United States
7.1.1.2 United Kingdom
7.1.1.3 EU4
7.1.1.4 India
7.1.1.5 Japan
7.1.2 Diagnosed Cases, by Country
7.1.2.1 United States
7.1.2.2 United Kingdom
7.1.2.3 EU4
7.1.2.4 India
7.1.2.5 Japan
7.1.3 Treatment Seeking Rate, by Country
7.1.3.1 United States
7.1.3.2 United Kingdom
7.1.3.3 EU4
7.1.3.4 India
7.1.3.5 Japan
8 Vertigo Market Landscape - 8 Major Markets
8.1 Vertigo Market: Developers Landscape
8.1.1 Analysis by Year of Establishment
8.1.2 Analysis by Company Size
8.1.3 Analysis by Region
8.2 Vertigo Market: Product Landscape
8.2.1 Analysis by Drugs
8.2.2 Analysis by Route of Administration
9 Vertigo Market Challenges and Unmet Needs
9.1 Treatment Pathway Challenges
9.2 Compliance and Drop-Out Analysis
9.3 Awareness and Prevention Gaps
10 Cost of Treatment
11 Vertigo Market Dynamics
11.1 Market Drivers and Constraints
11.2 SWOT Analysis
11.2.1 Strengths
11.2.2 Weaknesses
11.2.3 Opportunities
11.2.4 Threats
11.3 PESTEL Analysis
11.3.1 Political
11.3.2 Economic
11.3.3 Social
11.3.4 Technological
11.3.5 Legal
11.3.6 Environment
11.4 Porter’s Five Forces Model
11.4.1 Bargaining Power of Suppliers
11.4.2 Bargaining Power of Buyers
11.4.3 Threat of New Entrants
11.4.4 Threat of Substitutes
11.4.5 Degree of Rivalry
11.5 Key Demand Indicators
11.6 Key Price Indicators
11.7 Industry Events, Initiatives, and Trends
11.8 Value Chain Analysis
12 Vertigo Market Segmentation (218-2034) - 8 Major Markets
12.1 Vertigo Market (2018-2034) by Type
12.1.1 Market Overview
12.1.2 Peripheral Vertigo
12.1.3 Central Vertigo
12.2 Vertigo Market (2018-2034) by Drugs
12.2.1 Market Overview
12.2.2 Anticholinergics
12.2.3 Antihistamines
12.2.4 Others
12.3 Vertigo Market (2018-2034) by Route of Administration
12.3.1 Market Overview
12.3.2 Oral
12.3.3 Parenteral
12.3.4 Others
12.4 Vertigo Market (2018-2034) by End User
12.4.1 Market Overview
12.4.2 Hospitals
12.4.3 Clinics
12.4.4 Others
12.5 Vertigo Market (2018-2034) by Region
12.5.1 Market Overview
12.5.2 United States
12.5.3 EU-4 and the United Kingdom
12.5.3.1 Germany
12.5.3.2 France
12.5.3.3 Italy
12.5.3.4 Spain
12.5.3.5 United Kingdom
12.5.4 Japan
12.5.5 India
13 United States Vertigo Market (218-2034)
13.1 United States Vertigo Market Historical Value (2018-2024)
13.2 United States Vertigo Market Forecast Value (2025-2034)
13.3 United States Vertigo Market (2018-2034) by Type
13.3.1 Market Overview
13.3.2 Peripheral Vertigo
13.3.3 Central Vertigo
13.4 United States Vertigo Market (2018-2034) by Drugs
13.4.1 Market Overview
13.4.2 Anticholinergics
13.4.3 Antihistamines
13.4.4 Others
13.5 United States Vertigo Market (2018-2034) by Route of Administration
13.5.1 Market Overview
13.5.2 Oral
13.5.3 Parenteral
13.5.4 Others
13.6 United States Vertigo Market (2018-2034) by End User
13.6.1 Market Overview
13.6.2 Hospitals
13.6.3 Clinics
13.6.4 Others
14 EU-4 and United Kingdom Vertigo Market (218-2034)
14.1 EU-4 and United Kingdom Vertigo Market Historical Value (2018-2024)
14.2 EU-4 and United Kingdom Vertigo Market Forecast Value (2025-2034)
14.3 EU-4 and United Kingdom Vertigo Market (2018-2034) by Type
14.3.1 Market Overview
14.3.2 Peripheral Vertigo
14.3.3 Central Vertigo
14.4 EU-4 and United Kingdom Vertigo Market (2018-2034) by Drugs
14.4.1 Market Overview
14.4.2 Anticholinergics
14.4.3 Antihistamines
14.4.4 Others
14.5 EU-4 and United Kingdom Vertigo Market (2018-2034) by Route of Administration
14.5.1 Market Overview
14.5.2 Oral
14.5.3 Parenteral
14.5.4 Others
14.6 EU-4 and United Kingdom Vertigo Market (2018-2034) by End User
14.6.1 Market Overview
14.6.2 Hospitals
14.6.3 Clinics
14.6.4 Others
15 Japan Vertigo Market
15.1 Japan Vertigo Market Historical Value (2018-2024)
15.2 Japan Vertigo Market Forecast Value (2025-2034)
15.3 Japan Vertigo Market (2018-2034) by Type
15.3.1 Market Overview
15.3.2 Peripheral Vertigo
15.3.3 Central Vertigo
15.4 Japan Vertigo Market (2018-2034) by Drugs
15.4.1 Market Overview
15.4.2 Anticholinergics
15.4.3 Antihistamines
15.4.4 Others
15.5 Japan Vertigo Market (2018-2034) by Route of Administration
15.5.1 Market Overview
15.5.2 Oral
15.5.3 Parenteral
15.5.4 Others
15.6 Japan Vertigo Market (2018-2034) by End User
15.6.1 Market Overview
15.6.2 Hospitals
15.6.3 Clinics
15.6.4 Others
16 India Vertigo Market
16.1 India Vertigo Market (2018-2034) Historical Value (2018-2024)
16.2 India Vertigo Market (2018-2034) Forecast Value (2025-2034)
16.3 India Vertigo Market (2018-2034) by Type
16.3.1 Market Overview
16.3.2 Peripheral Vertigo
16.3.3 Central Vertigo
16.4 India Vertigo Market (2018-2034) by Drugs
16.4.1 Market Overview
16.4.2 Anticholinergics
16.4.3 Antihistamines
16.4.4 Others
16.5 India Vertigo Market (2018-2034) by Route of Administration
16.5.1 Market Overview
16.5.2 Oral
16.5.3 Parenteral
16.5.4 Others
16.6 India Vertigo Market (2018-2034) by End User
16.6.1 Market Overview
16.6.2 Hospitals
16.6.3 Clinics
16.6.4 Others
17 Regulatory Framework
17.1 Regulatory Overview
17.2 US FDA
17.3 EU EMA
17.4 Japan PMDA
17.5 India CDSCO
17.6 Others
18 Clinical Trials Analysis
18.1 Analysis by Trial Registration Year
18.2 Analysis by Trial Status
18.3 Analysis by Trial Phase
18.4 Analysis by Therapeutic Area
18.5 Analysis by Geography
19 Grants Analysis
19.1 Analysis by Year
19.2 Analysis by Amount Awarded
19.3 Analysis by Issuing Authority
19.4 Analysis by Grant Application
19.5 Analysis by Funding Institute
19.6 Analysis by NIH Departments
19.7 Analysis by Recipient Organization
20 Funding and Investment Analysis
20.1 Analysis by Funding Instances
20.2 Analysis by Type of Funding
20.3 Analysis by Funding Amount
20.4 Analysis by Leading Players
20.5 Analysis by Leading Investors
20.6 Analysis by Geography
21 Strategic Initiatives
21.1 Analysis by Partnership Instances
21.2 Analysis by Type of Partnership
21.3 Analysis by Leading Players
21.4 Analysis by Geography
22 Supplier Landscape
22.1 Market Share by Top 5 Companies
22.2 Pfizer Inc.
22.2.1 Financial Analysis
22.2.2 Product Portfolio
22.2.3 Demographic Reach and Achievements
22.2.4 Companies News and Developments
22.2.5 Certifications
22.3 Sanofi S.A.
22.3.1 Financial Analysis
22.3.2 Product Portfolio
22.3.3 Demographic Reach and Achievements
22.3.4 Companies News and Developments
22.3.5 Certifications
22.4 Viatris Inc.
22.4.1 Financial Analysis
22.4.2 Product Portfolio
22.4.3 Demographic Reach and Achievements
22.4.4 Companies News and Developments
22.4.5 Certifications
22.5 Casper Pharma LLC
22.5.1 Financial Analysis
22.5.2 Product Portfolio
22.5.3 Demographic Reach and Achievements
22.5.4 Companies News and Developments
22.5.5 Certifications
22.6 Auris Medical AG
22.6.1 Financial Analysis
22.6.2 Product Portfolio
22.6.3 Demographic Reach and Achievements
22.6.4 Companies News and Developments
22.6.5 Certifications
22.7 Apsen Farmaceutica S.A.
22.7.1 Financial Analysis
22.7.2 Product Portfolio
22.7.3 Demographic Reach and Achievements
22.7.4 Companies News and Developments
22.7.5 Certifications
22.8 Sound Pharmaceuticals, Incorporated
22.8.1 Financial Analysis
22.8.2 Product Portfolio
22.8.3 Demographic Reach and Achievements
22.8.4 Companies News and Developments
22.8.5 Certifications
23 Vertigo Treatment Drugs - Distribution Model (Additional Insight)
23.1 Overview
23.2 Potential Distributors
23.3 Key Parameters for Distribution Partner Assessment
24 Key Opinion Leaders (KOL) Insights (Additional Insight)
25 Payment Methods (Additional Insight)
25.1 Government Funded
25.2 Private Insurance
25.3 Out-of-Pocket

Companies Mentioned

  • Sanofi S.A
  • Pfizer Inc.
  • Sound Pharmaceuticals

Table Information